Picankibart

匹康奇拜单抗

Report date: 2026/05/28 20:00:21

Base Information

Drug NamePicankibart
Drug Alias Name信美悦PECONDLEIBI-112IB112
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionInterleukin-23 subunit p19 inhibitors
TargetsInterleukin-23 subunit p19
Therapy Area/IndicationsPlaque psoriasisPsoriasisCrohn Disease +[5] 
Global Approved IndicationsPlaque psoriasis
Approved Indications in ChinaPlaque psoriasis
Original Approved Country/TerritoryMainland China
Original Approved Date2025/11/25
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesInnovent Biologics(Suzhou) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesInnovent Biologics (Hangzhou) Co., Ltd.Xinda Biomedical Technology (Hangzhou) Co LtdInnovent Biologics(Suzhou) Co Ltd
Inactive CompaniesN/A
Active IndicationsPlaque psoriasisPsoriasisCrohn Disease +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A